Navigation Links
Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published

he Amgen Oncology Assistance program will be available for U.S. cancer patients and will launch in October. For more information, please visit www.amgen.com.

About Colorectal Cancer

Colorectal cancer is the third most common cancer diagnosed in men and in women in the United States. The American Cancer Society estimated that about 112,340 new cases of colon cancer and 41,420 new cases of rectal cancer will be diagnosed in 2007. Colorectal cancer is the second leading cause of cancer death among men and women in the United States and Canada (after lung cancer). It has been estimated that 52,180 people will die from colorectal cancer in 2007. That means that one person in the United States dies of colorectal cancer every 9.3 minutes.

About Vectibix

Although EGF receptors normally help regulate the growth of many different cells in the body, these receptors also can stimulate cancer cells to grow. In fact, some cancer cells actually require signals mediated by EGF receptors for their survival. Residing on the surfaces of these tumor cells, EGF receptors are activated when naturally occurring proteins in the body, such as epidermal growth factor (EGF) or transforming growth factor alpha (TGF-alpha), bind to them. This binding changes the shape of the EGF receptors, which, in turn, triggers internal cellular signals that stimulate tumor cell growth. Vectibix binds to EGF receptors, preventing the natural ligands such as EGF and TGF-alpha from binding to the receptors and interfering with the signals that might otherwise stimulate growth and survival of the cancer cell.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
2. Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
3. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
4. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
5. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
6. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:9/30/2014)...  Tasly Pharmaceuticals, Inc., the world,s leader in ... the launch of Deepure. Deepure is ... and women concerned with supporting their overall health ... while helping keep their health care cost down.  ... formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and Pro-Memory ...
(Date:9/30/2014)... 2014 Aileron Therapeutics, Inc. - Product ... Markets Direct,s, ,Aileron Therapeutics, Inc. - Product Pipeline ... Aileron Therapeutics, Inc.,s pharmaceutical research and development focus. ... current therapeutic developmental pipeline of Aileron Therapeutics, Inc.,s, ... assessment by drug target, mechanism of action (MoA), ...
(Date:9/30/2014)... , September 30, 2014 ... research report the "Glycobiology/Glycomics Market by Product [Enzymes ... MALDI-TOF), Kits, and Reagents], Application (Immunology, Oncology) ... to 2019", published by MarketsandMarkets, provides a ... challenges, opportunities, current market trends, and strategies ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... Orally Dissolving Film StripBioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF ... products division of a wholly owned subsidiary of Par ... provides an update on two of its pipeline products. ... 7, 2009, Strativa submitted a New Drug Application (NDA) ...
... April 8 Phase III data, published online this ... Metabolism , showed that arzoxifene, an investigational selective estrogen ... Company (NYSE: LLY ), significantly increased lumbar ... postmenopausal women with normal or low bone mass, versus ...
Cached Medicine Technology:Strativa Pharmaceuticals Provides Product Pipeline Update 2Strativa Pharmaceuticals Provides Product Pipeline Update 3Strativa Pharmaceuticals Provides Product Pipeline Update 4Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 2Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 3Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 4
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- There,s no ... prevent type 2 diabetes, a new study says. ... vitamin D might protect people against type 2 diabetes, ... deficiency and the blood sugar disease. In this ... and vitamin D by focusing on genes that control ...
(Date:9/30/2014)... to cut climate-changing carbon emissions will reduce other ... benefits, according to a new study released today. ... options included in the final Clean Power Plan, ... premature deaths and hospitalizations, and hundreds of heart ... the new study, Health Co-benefits of Carbon Standards ...
(Date:9/30/2014)... cancer is the leading cause of cancer death in ... so many medical professionals encourage women to get mammograms, ... a minority of suspicious mammograms actually leads to a ... worry for women and their familiesnot to mention the ... and biopsies. , Recently, a different type of ...
(Date:9/30/2014)... Utah (PRWEB) September 30, 2014 A new ... Ohio State University studied the impact of stress on metabolism ... burger and french fries from a fast food restaurant, about ... woman’s resting metabolism for 20 minutes every hour for 7 ... Results showed that women who had experienced a stressful event ...
(Date:9/30/2014)... 2014 Research by UC Irvine immunologists reveals new ... on a vital process that determines how the body,s ... version of Nature Immunology , neurology professor Dr. ... for Immunology colleagues describe a critical mechanism underlying how ... bloodstream. , A T cell is a type of ...
Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:'Virtual breast' could improve cancer detection 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:UCI study uncovers important process for immune system development 2
... By Alan Mozes HealthDay Reporter , THURSDAY, March ... a common facet of dating for America,s adolescents, a new ... graders found that more than 37 percent of 11- to ... psychological violence, and almost one in six said they had ...
... (HealthDay News) -- Although eight states boosted their sales taxes ... in the number of such increases by states compared to ... Control and Prevention shows. One thing that smoking prevention ... as cigarette prices go up, the CDC said. ...
... common kidney cancer subtype, face a low risk of tumour ... findings of a multi-centre study of nearly 600 patients published ... . "Because papillary renal cell carcinoma ... the small number of patients enrolled in individual studies makes ...
... , WEDNESDAY, March 28 (HealthDay News) -- Tourists over age 65 ... die from the disease than those ages 18 to 35, a ... from more than 25,000 U.K. patients also found that the malaria ... West Africa. The risk of dying from malaria, an infection ...
... As part of an isolated indigenous group in central ... fishing, and clearing land by hand to grow crops. Their ... day might imply they have higher than average male testosterone ... of Washington have found, however, that the baseline testosterone level ...
... the World Health Organization (WHO) estimates that 20.1 million ... 1 and 2 across 9 world regions in 2005. ... Hepatology , a journal published by Wiley-Blackwell on ... Liver Diseases, there were 3.4 million symptomatic cases, 70,000 ...
Cached Medicine News:Health News:Dating Violence Common by 7th Grade: Survey 2Health News:Dating Violence Common by 7th Grade: Survey 3Health News:States' Efforts to Boost Cigarette Taxes Slows: CDC 2Health News:Kidney cancer subtype study finds low recurrence and cancer death rates 2Health News:Older Travelers at Much Higher Risk of Dying From Malaria 2Health News:Low testosterone level in Amazonian tribe responds to competition 2Health News:Over 20 million individuals infected with hepatitis E in Asia and Africa 2
... The Guidant Flextend lead ... pace/sense lead with an ... extendable/retractable helix design offers ... for permanent implantation in ...
... a low profile implantable bipolar fixed ... of either the atrium or the ... with a screwdriver shape stylet which ... The ring tip and fixation screw ...
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Implantable medical grade silicone sleeve for adapting a 5 mm (01) connector to a 6 mm (02) connector....
Medicine Products: